ESMO/LinkedIn
May 27, 2025, 12:16
The Most Recent Articles from ESMOBreast25 on latest Developments in Breast Cancer
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Interested in the latest developments in Breast Cancer?
Check out some of the most recent articles from ESMOBreast25:
- Adding adjuvant pertuzumab demonstrates prolonged survival benefit after 10+ years in HER2+ breast cancer.
- Who benefits from immunotherapy for breast cancer?
- Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers.
- Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer TNBC.
- Shaping the future for young women facing breast cancer.
Stay up-to-date with the cutting-edge developments in oncology.
Follow the ESMO Daily Reporter, your trusted source for news and expert opinions tailored to the Oncology Community.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 27, 2025, 14:17
May 27, 2025, 13:44
May 27, 2025, 13:35
May 27, 2025, 13:12
May 27, 2025, 13:02
May 27, 2025, 12:50